BCT:CC News and Press, Briacell Therapeutics Corp. From 05/25/23

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer treatments. However, there may be hope on the horizon for the 43,000 women that die every ye...

Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotech...

PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is ple...

A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And unfortunately, as it stands, breast cancer dea...

Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell’...

A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive breast cancer. And breast cancer deaths are estimated to be more than 43,000 per year ...

15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. The Bria-IMT ™ combination regimen...

SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOU...

2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...

PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has ...